Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Dylan P Steen, Mary Ann Lukas, Elizabeth Tarka, P Gabriel Steg, Judith S Hochman, Christoph Bode, Aldo P Maggioni, KyungAh Im, Jennifer B Shannon, Richard Y Davies, Sabina A Murphy, Sharon E Crugnale, Stephen D Wiviott, Marc P Bonaca, David Watson, W Douglas Weaver, Patrick W SerruysChristopher P Cannon, Dylan L Steen, SOLID-TIMI 52 Investigators, Jørgen Lykke Jeppesen, Jens Erik Rokkedal Nielsen

353 Citationer (Scopus)

Abstract

IMPORTANCE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.

OBJECTIVE: To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event.

DESIGN, SETTING, AND PARTICIPANTS: SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation myocardial infarction [MI]) at 868 sites in 36 countries.

INTERVENTIONS: Patients were randomized to either once-daily darapladib (160 mg) or placebo on a background of guideline-recommended therapy. Patients were followed up for a median of 2.5 years between December 7, 2009, and December 6, 2013.

MAIN OUTCOMES AND MEASURES: The primary end point (major coronary events) was the composite of coronary heart disease (CHD) death, MI, or urgent coronary revascularization for myocardial ischemia. Kaplan-Meier event rates are reported at 3 years.

RESULTS: During a median duration of 2.5 years, the primary end point occurred in 903 patients in the darapladib group and 910 in the placebo group (16.3% vs 15.6% at 3 years; hazard ratio [HR], 1.00 [95% CI, 0.91-1.09]; P = .93). The composite of cardiovascular death, MI, or stroke occurred in 824 in the darapladib group and 838 in the placebo group (15.0% vs 15.0% at 3 years; HR, 0.99 [95% CI, 0.90-1.09]; P = .78). There were no differences between the treatment groups for additional secondary end points, for individual components of the primary end point, or in all-cause mortality (371 events in the darapladib group and 395 in the placebo group [7.3% vs 7.1% at 3 years; HR, 0.94 [95% CI, 0.82-1.08]; P = .40). Patients were more likely to report an odor-related concern in the darapladib group vs the placebo group (11.5% vs 2.5%) and also more likely to report diarrhea (10.6% vs 5.6%).

CONCLUSIONS AND RELEVANCE: In patients who experienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy and initiated within 30 days of hospitalization did not reduce the risk of major coronary events.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01000727.

OriginalsprogEngelsk
TidsskriftJ A M A: The Journal of the American Medical Association
Vol/bind312
Udgave nummer10
Sider (fra-til)1006-15
Antal sider10
ISSN0098-7484
DOI
StatusUdgivet - 10 sep. 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater